Urology & Oncology
Bladder Cancer | Clinique Omicron Quebec
Obtenir un avis adapté à votre situation
Consultation en clinique ou en téléconsultation, partout au Québec.
Bladder cancer is the most common malignant tumor of the urinary tract and the fourth most common cancer among men in North America. In Canada, approximately 12,500 new cases are diagnosed each year, with a male-to-female ratio of about 3 to 4 to 1—although the prognosis for women is generally poorer, due to more frequent delays in diagnosis (hematuria is often mistakenly attributed to a urinary tract infection or a gynecological cause). More than 90% of bladder cancers are urothelial carcinomas (formerly called transitional cell carcinomas)—developing from the urothelium, the epithelium lining the upper and lower urinary tract. There are two main fundamental prognostic and therapeutic categories: non-muscle-invasive bladder tumors (NMIBT—stages Ta, T1, CIS), which account for 75 to 80% of new cases and for which conservative treatment is possible but carries a very high risk of recurrence (50 to 70% at 5 years), and muscle-invasive tumors (MIBT—stages T2 to T4), which require radical surgery (total cystectomy) or conservative chemoradiotherapy, and for which the prognosis is significantly less favorable. The most common and characteristic presenting symptom is painless gross hematuria—pink or blood-red urine without associated pain—present in 80 to 85% of cases at the time of diagnosis. This symptom, even if episodic or fleeting, should always prompt a cystoscopy in any adult over 35 years of age, regardless of their risk profile, as painless gross hematuria can never be attributed to a benign cause without a complete evaluation of the urinary tract.
Risk factors
- Smoking—the leading modifiable risk factor: smoking accounts for 50 to 65% of bladder cancers in men and 20 to 30% in women; Tobacco carcinogens (aromatic amines, nitrosamines, polycyclic aromatic hydrocarbons) are excreted in high concentrations in urine—prolonged contact with the bladder urothelium; the risk is 2 to 4 times higher in active smokers compared to non-smokers; quitting smoking gradually reduces the risk, but it remains high for 20 years after quitting
- Occupational exposure to aromatic amines: the second leading cause of bladder cancer—accounting for 20 to 25% of cases; high-risk occupations: chemical and petrochemical industries, dry cleaning and textile dyeing (benzidine, beta-naphthylamine, 4-aminobiphenyl—IARC Group 1 carcinogens), rubber and plastics industries, hairdressers (older hair dyes), foundries, aluminum and paint industries; latency period of 15 to 40 years between exposure and cancer development; may be recognized as an occupational disease in Canada based on the exposure table
- Urinary schistosomiasis (Schistosoma haematobium): main cause of squamous cell carcinoma of the bladder (non-urothelial) in endemic countries (sub-Saharan Africa, Middle East, Nile) - chronic inflammation of the bladder wall by parasite eggs → squamous cell metaplasia → carcinoma; accounts for 75 % of bladder cancers in Egypt
- Anterior pelvic radiotherapy: anterior pelvic radiotherapy treatment (cervical cancer, prostate cancer, rectal cancer) → 2 to 4 times increased risk of radiation-induced bladder cancer — 10 to 20 years after irradiation; must be systematically considered for hematuria in patients with a history of pelvic radiotherapy
- Cyclophosphamide (alkylating agent): cyclophosphamide chemotherapy → urotoxic metabolite (acrolein) excreted in urine → chronic hemorrhagic cystitis → urothelial cancer (9x risk after prolonged use); prevention with hyperhydration and MESNA (2-mercaptoethanesulfonate sodium) during chemotherapy cycles; latency of 5 to 15 years
- Pioglitazone (antidiabetic - thiazolidinedione): pharmacovigilance signal confirmed in several epidemiological studies – increased risk of bladder cancer (× 1.2 to 1.4) with prolonged use > 24 months; withdrawn or not recommended in some countries; contraindicated if history or risk factor for bladder cancer according to Health Canada
- Aristolochia (aristolochic acid): plant used in traditional Asian medicine and in some fraudulent weight-loss diets — potent urothelial carcinogen (aristolochic acid nephropathy + upper urinary tract and bladder cancer); numerous cases described in Belgium, Taiwan, and China
- Chronic urinary tract infections and bladder stones: chronic inflammation of the bladder lining → increased risk of squamous cell carcinoma (less frequent than urothelial carcinoma); patients with long-term indwelling urinary catheters (paraplegics, neurogenic bladder)
Symptoms
- Painless gross hematuria: a cardinal symptom present in 80 to 85% of bladder cancers at the time of diagnosis—pink, bright red, or reddish-brown urine (port wine or Coca-Cola-colored hematuria) without associated pain; the absence of pain is characteristic and should suggest a neoplastic rather than an infectious cause (where hematuria is often accompanied by dysuria); hematuria may be episodic, intermittent, and self-limiting—it may disappear for several weeks before reappearing—this intermittent nature should in no way be reassuring and should not lead to a decision not to investigate
- Isolated microscopic hematuria: detected by urine dipstick or urine culture (red blood cells > 3/field) without urinary symptoms — indicates bladder cancer in 5 to 10% of cases among patients over 50 years of age with risk factors; warrants cystoscopy and imaging of the upper urinary tract in any adult over 35 years of age with risk factors (smoking, occupational exposure) or over 50 years of age without identified risk factors
- Bladder irritation symptoms (irritative syndrome): frequent urination, urgency, and dysuria—present in 20 to 30% of bladder cancers, particularly in carcinoma in situ (CIS) and high-grade multifocal tumors; often mistakenly attributed to a urinary tract infection or overactive bladder — a repeated negative urine culture in a patient with persistent irritative syndrome warrants a cystoscopy
- Symptoms of locally advanced forms: pelvic or lumbar pain (invasion of pelvic walls or obstruction of ureters); bilateral hydronephrosis (obstruction of ureteral meatuses → obstructive renal failure); lower limb edema (lymphatic or venous compression); urinary retention (obstruction of the bladder neck)
- Metastatic symptoms: bone pain (bone metastases - pelvis, spine, femur); inguinal or supraclavicular lymphadenopathy; cough, dyspnea (pulmonary metastases); jaundice (liver metastases); poor general condition, weight loss, cachexia
ℹ️
Painless gross hematuria in an adult over 35 years of age should be considered neoplastic in origin until proven otherwise and investigated with cystoscopy and urinary tract imaging—even if it is isolated, fleeting, or another benign explanation seems obvious (urinary tract infection, anticoagulants). Attributing it to a urinary tract infection without complete urological investigation is one of the main causes of delayed bladder cancer diagnosis.
Diagnosis and assessment
- Cystoscopy: Gold standard—direct visualization of the bladder lining via the urethra (flexible or rigid cystoscope); localization, macroscopic appearance (papillary vs. solid vs. flat), number, and size of lesions; biopsies of suspicious lesions and random biopsies of normal-appearing areas if CIS is suspected; blue light cystoscopy (fluorescence hexaminolevulinate—Cysview/Hexvix)—improves detection of flat lesions (CIS) and small volume tumors not visible under white light; narrow band imaging (NBI) cystoscopy—alternative to blue light
- Diagnostic and therapeutic transurethral resection of the bladder tumor (TURBT): endoscopic resection of all visible lesions under general anesthesia; sending the resected specimen to the pathology department to determine the histological type, grade (low-grade vs. high-grade—WHO 2004 classification), and depth of invasion (T stage—presence or absence of detrusor muscle in the specimen); absence of detrusor muscle in the resection specimen = incomplete TURBT → mandatory repeat TURBT 4 to 6 weeks later; urinary cytology on fresh urine (3 consecutive samples)—high sensitivity for high-grade tumors and CIS (85–90% %) but low for low-grade tumors (20–30% %)
- Staging imaging: contrast-enhanced thoraco-abdominal-pelvic CT scan (3-phase uro-CT) — assessment of local spread (invasion of the perivesical fat and adjacent organs) and distant spread (lymph nodes, liver, lungs, bones); evaluation of the upper urinary tract (synchronous urothelial tumors in 5 out of 10 cases); pelvic MRI — better resolution for assessing muscle invasion (T2 vs. T3) and extension to adjacent organs than CT; bone scan if symptoms suggestive of bone metastases
- Urinary markers: NMP22 (nuclear matrix protein 22), BTA (bladder tumor antigen), urine FISH (UroVysion — detection of chromosomal abnormalities in urothelial cells) — variable sensitivity and specificity; used in addition to urine cytology for monitoring high-risk NMIBC and reducing the frequency of surveillance cystoscopies (not yet replaced by circulating tumor DNA tests in current practice)
Classification and treatment according to stage
| Stadium | Description | Standard treatment |
|---|---|---|
| Your low grade | Non-invasive papillary tumor, low grade — favorable prognosis, low risk of progression | Complete TURF; single intravesical instillation of mitomycin C within 24 hours after TURF (reduces the risk of recurrence by 40%); cystoscopic follow-up at 3 months, 6 months, and then annually, depending on the course of the disease |
| Ta high grade / T1 / CIS | High-grade neoplasia or lamina propria invasion (T1) or carcinoma in situ (CIS — flat lesion of high grade, highly recurrent) — significant risk of muscle progression | RTUV + repeat RTUV at 4–6 weeks (mandatory); intravesical instillations of BCG (Bacillus Calmette-Guérin): induction for 6 weeks + maintenance for 1–3 years (SWOG maintenance protocol) — reduces the risk of progression by 30–40% in %; early radical cystectomy considered for multifocal CIS refractory to BCG or recurrent high-grade T1 |
| T2 (superficial muscle invasion) | Invasion of the superficial detrusor muscle (T2a) or deep detrusor muscle (T2b) - Tumor invading the muscle (TIM) | Cisplatin-based neoadjuvant chemotherapy (dose-dense MVAC or gemcitabine-cisplatin, 3–4 cycles) + radical cystectomy with extended lymph node dissection — 5–8% reduction in mortality; OR conservative chemoradiotherapy (CCRT) for patients ineligible for cystectomy or refusing radical surgery — TMT protocol (trimodality therapy: maximal suprapubic radiotherapy + radiosensitizing chemotherapy + 64–66 Gy of radiotherapy) — 5-year survival similar to cystectomy in selected cases |
| T3–T4 (peri-vesical or adjacent extension) | Invasion of perivesical fat (T3) or adjacent organs—prostate, uterus, vagina, pelvic wall (T4) | Neoadjuvant chemotherapy (if cisplatin-eligible) + radical cystectomy (if resectable) OR chemoradiotherapy; if T4b (fixed wall) → induction systemic chemotherapy then re-evaluation of resectability |
| Stage IV (metastatic) | Distant lymph nodes or visceral metastases | First-line cisplatin-eligible: gemcitabine + cisplatin (GC) ± pembrolizumab (KEYNOTE-361) or nivolumab (CheckMate-901); first-line cisplatin-ineligible: pembrolizumab (KEYNOTE-052 — response rate 29% %) or atezolizumab if PD-L1+; Second-line: pembrolizumab (KEYNOTE-045) — median survival 10.3 months vs. 7.4 months with chemotherapy; enfortumab vedotin (EV — anti-Nectin-4, ADC) — response rate 40–52% in second- and third-line settings; EV + pembrolizumab (EV-302) — FDA-approved in 2024 for first-line metastatic treatment — a therapeutic breakthrough (median survival 31.5 months vs. 16.1 months with standard of care) |
Post-treatment monitoring of NMVT
- Risk of recurrence and progression: non-muscle-invasive bladder tumors (NMBTs) recur in 50–70% of cases at 5 years following transurethral resection of the tumor (TURT) alone (without BCG)—which is why regular cystoscopic follow-up is essential; the risk of progression to a muscle-invasive tumor is 15–40% depending on the initial grade and stage; Risk stratification (low, intermediate, or high risk according to the EORTC or CUETO tables) guides the frequency of follow-up and the indications for adjuvant instillations
- Cystoscopic monitoring protocol (high risk): cystoscopy + urinary cytology 3 months after RTUV; if negative: cystoscopy every 3 months for 2 years, then every 6 months for 3 years, then annually for life; annual CT scan of the urinary tract for monitoring the upper urinary tract (risk of upper urinary tract urothelial carcinoma of 2–4 % at 5 years)
- BCG-refractory or BCG-unresponsive: Intravestical Pembrolizumab (KEYNOTE-676) — positive trial published 2024; Nadofaragene firadenovec (intravestical recombinant adenovirus expressing IFN-α2b) — FDA approved 2023 for BCG-refractory CIS; Radical cystectomy if progression despite conservative treatment
Prognosis - 5-year survival
| Stage at diagnosis | Survival to 5 years | Remarks |
|---|---|---|
| TVNIM Ta–T1–CIS | 85-95 % | Excellent survival but frequent recurrence (50–70% of % cases) — a chronic disease requiring lifelong monitoring; muscle progression in 15–40% of high-risk % cases |
| T2 (superficial muscle) | 60–75 % | Radical cystectomy + neoadjuvant chemotherapy; improved survival compared to surgery alone |
| T3–T4 (locally advanced) | 25–45 1st–3rd | Surgery possible in some cases; neoadjuvant chemotherapy essential |
| Stage IV (metastatic) | 5-15 % | Grim prognosis until 2024; EV + pembrolizumab (EV-302) has transformed the prognosis — median survival 31.5 months (vs 16.1 months with GC); hope for further improvement with next-generation ADCs |
Gross hematuria - immediate consultation recommended
Painless gross hematuria (pink or red urine without burning during urination) in an adult over 35 years old should prompt medical consultation within the following days for a prescription of cystoscopy and urinary tract imaging—even if it occurs only once, is brief, or a benign cause seems likely. Never conclude it is a urinary tract infection or due to physical exertion without a complete urological investigation in the presence of gross hematuria. A delay of several months in diagnosing bladder cancer can transform a curable NMIBC into a locally advanced BC with a poor prognosis. 911 if hematuria is very abundant with clots, acute urinary retention or signs of hemorrhagic shock.
Consult at Clinique Omicron
Les médecins de Clinique Omicron évaluent tout épisode d'hématurie, prescrivent le bilan initial (ECBU, NFS, créatinine, échographie des voies urinaires) et orientent vers l'urologue partenaire pour la cystoscopie et la prise en charge urologique complète. Le suivi des patients traités pour un cancer de la vessie est assuré en coordination avec l'équipe urologique spécialisée. Des consultations sont disponibles dans nos points de service au Québec ainsi qu'en télémédecine. Pour prendre rendez-vous, choisissez votre service en ligne.
The content of this page is provided for informational purposes only and does not substitute for the advice of a qualified healthcare professional. Any gross hematuria in an adult over 35 years of age warrants immediate and thorough urological investigation.
Omicron Clinic
Need to consult a doctor?
En clinique ou en télémédecine, partout au Québec.
Reçus pour assurances. Téléconsultation 7 j/7. Sans médecin de famille requis.